(Image Credit: AdobeStock/conceptcafe)
Apellis Pharmaceuticals Inc announced a corporate restructuring to drive growth of pegcetacoplan injection (SYFOVRE) and pegcetacoplan (EMPAVELI), which the company said in a release would “position it for long-term success.”
According to a company news release, the planned restructuring will include cost reduction initiatives that align with the companys near-term priorities and are expected to result in up to $300 million in total cost savings through 2024.
Cedric Francois, MD, PhD, co-founder and CEO of Apellis, said in the news release the company is positioning itself for future growth.
We are taking important actions to strengthen our ability to invest in growth opportunities and sup…
Read the full article at: https://www.ophthalmologytimes.com/view/apellis-announces-corporate-restructuring-to-drive-growth-of-pegcetacoplan